SGO 2025

微专辑

扫描二维码

可查看更多内容

 

第56届美国妇科肿瘤学年会（SGO 2025）于2025年3月14-17日在西雅图盛大召开。作为全球范围内最权威的妇科肿瘤学术会议之一，SGO年会将为业内同道提供交流最新研究成果和临床经验的平台，展示具有创新性及前沿视角的观点和思路。

 

会上，来自希望之城国家医疗中心Min Guan教授一项“靶向宫颈癌的ENG-CAR T细胞疗法”的研究进展入选焦点论坛，在会议期间，《肿瘤瞭望》特邀Min Guan教授接受专访，分享宫颈癌领域CAR-T细胞疗法探索进展及未来展望，特此整理，以飨读者。

 

Min Guan教授：在宫颈癌这一领域，临床上还没有开发出相应的CAR-T细胞疗法。因此，我们非常希望可以打破壁垒，开发出第一个用于宫颈癌治疗的生物标志物，以改进宫颈癌免疫疗法的临床现状。正如我们在会议上讨论的那样，这是一个针对患者自身T细胞重编程的载体，通过这个载体，T细胞能够识别并结合到肿瘤细胞表面的特定抗原上，随后激活T细胞内的杀伤机制，从而释放细胞毒素，杀死肿瘤细胞。在既往血液肿瘤领域相关临床研究中已证实，这些细胞可以在体内存活一年甚至更久。但在实体瘤中，CAR-T细胞疗法的开发可能会面临恶劣肿瘤微环境所带来的挑战。但本研究中ENG-CAR T细胞疗法的独特性在于其可以同时靶向肿瘤细胞及肿瘤微环境，所以我们有很大希望能够改善当前宫颈癌治疗的临床疗效。

 

目前，这项新技术仍在研发过程当中，处于临床前研究阶段，我们已经获得了专利保护。期待这项技术早日与大家见面，届时我们也将发布更多信息。但现在，我们仍需要对临床数据做更进一步的研究。

 

Prof.Min Guan：So within the cervical cancer field，clinically there are no CAR-T cells therapy has been developed yet.And that’s why we’re very interesting to develop this first marker targeting the service for cancer specifically，and to improve the current treatment of the immunotherapy.As we have discussed in meeting，this is a unique platform that reprogramming the patient’s own T cells and to give this T cells function to activate bind and kill the tumor.And these cells can persistent impatience circulation for up to 1 year or even longer from our blood cancer clinical trials.So solid tumor still may facing the challenge that the tumor micro environment is very hostile.And this CAR is unique，can target both tumor cells and tumor micro environment，so hopefully we could，you know，improve the outcome of the current treatment.

 

Now this novel technique is still ongoing.And we have mainly focusing on the preclinical stage yet.If we successfully get this public sooner，we already have the patent protected.So then we will release more information.But currently is operate clinical data that’s ongoing.

Min Guan教授：我们作为City of Hope的CAR-T细胞治疗平台之一，正在积极推进该研究的临床转化。其中，CAR-T细胞疗法的相关毒性需要我们持续密切关注，其安全性是在FDA获得临床研究审批（IND）的重要前提。现阶段临床前研究结果中，尚未在动物模型中观察到治疗相关毒性，展现了该疗法的临床应用前景，后续将扩大模型样本进一步验证。

 

现阶段对于宫颈癌的治疗尚缺乏特异性的免疫治疗手段，因此我认为这个领域需要尽快发展。基于ENG-CAR T细胞疗法这一新平台，我希望未来将其与VGF抗体、PD-1抗体以及CTLA-4抗体等免疫疗法相结合，为宫颈癌的治疗探索更多更加精准有效的治疗策略。

 

Prof.Min Guan：So currently，we are very carefully to moving forward regarding the application to the preclinical and translational.As our other CAR T cell therapy platform at City of Hope，we always have to test the on target of tumor toxicities before we can moving forward to get IND enabling at FDA.And we’re currently actively testing the toxicities about this CAR T cell therapy by using the animal model.And as long as our current observation，this therapy looks very promising as we haven’t seen the toxicities in mice.And we’re expanding to see more tumor cell lines issues and by using different models to verify that.

 

So I think this field need to be develops as soon as possible.And cervical cancers，there are no specific immunotherapy has been developed.And with this new platform，I wish we can do some more work with the combination therapies that has been used like the VGF antibody and PD-1 antibody and also the CTLA-4 antibody and together with the CAR T cell therapy，hopefully we could find some better answer.

 

Min Guan教授

希望之城国家医疗中心高级科学家